ARTICLE | Regulation
Final stretch
Why design of a postmarketing CV study has delayed Dynavax’s Heplisav-B, again
August 5, 2017 1:06 AM UTC
Following a long and bumpy regulatory road, it appears Heplisav-B from Dynavax Technologies Corp. is finally in the home stretch. But how the company and FDA handle the final hurdle -- the design of a postmarketing CV safety study -- may determine whether bigger challenges lie ahead.
What makes the problem interesting is that the patients in whom Heplisav-B is most effective are also those most at risk of myocardial infarction...
BCIQ Company Profiles